TERBUTALIN
Postthoracoscopy Neuropathic Pain
University Hospital, Strasbourg, FranceSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Postthoracoscopy Neuropathic Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atnc05 Allodynic Therapeutics, Inc | Phase 2/3 | NR |
Same molecule, other indications
TERBUTALIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →